Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc.（PCSA）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
pcsa · 股价预测 · 5 位分析师（近3月）· FMP · 更新于 2026年6月9日
分析师评级与共识
基于过去 3 个月内 5 位华尔街分析师
Buy
5 位分析师
共识
评级分布
12 个月目标价
High
$225
Consensus
$225
+9197.5% upside
Low
$225
Median: $225 · Last Close: $2.42
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
短期股价预测
Low Activity算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $2.44 | ↑ 0.78% |
1-day model range: $2.37–$2.51. Peak: $2.51 (+0.78%).
长期股价预测
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · PCSA · Jun 9, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-09-02 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-06-30 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-05 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-20 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-01 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-06-12 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-05-13 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-03-06 | Benchmark | Maintains | Speculative Buy→Speculative Buy |
| 2023-11-17 | Maxim Group | Downgrade ↓ | Buy→Hold |
Wall Street analysts have recently issued updated ratings on Processa Pharmaceuticals, Inc. (PCSA) stock. Of the recent 17 rating actions, 0 were upgrades and 1 were downgrades. 5 analysts currently cover PCSA.
分析师推荐趋势
PCSA analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$15M
↑ 44.0% YoY
Revenue Next Year
$10M
↓ 32.9% YoY
EPS This Year
$-10.25
EPS Next Year
$-6.00
↓ 41.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast PCSA EPS of $-10.25 for the current fiscal year, based on estimates from 1 analysts. The PCSA revenue forecast is $15M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
PCSA 股价预测由两类独立数据源支撑：来自 5 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。PCSA 的共识目标价为 $225.00（+9197.5% 上行空间），分析师共识为 Buy。
PCSA 的短期预测（明日）为 $2.44（+0.78%）。
Processa Pharmaceuticals, Inc. 在 NASDAQ 上市，代码 PCSA。PCSA 在 2027 年的整体展望偏积极，在覆盖分析师中约 80% 对应 Buy 共识。
常见问题
PCSA 预测 · 8 个问题根据 5 位华尔街分析师，PCSA 的 12 个月平均目标价为 $225.00，最高 $225.00、最低 $225.00。若有图表，中位目标价可在上方查看。相对当前价 $2.42，隐含约 +9197.5% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.